Grace Therapeutics Inc (GRCE)
3.125
+0.02
(+0.81%)
USD |
NASDAQ |
Oct 31, 16:00
3.15
+0.02
(+0.80%)
After-Hours: 20:00
Grace Therapeutics Enterprise Value: 12.28M for Oct. 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 31, 2024 | 12.28M |
| October 30, 2024 | 12.02M |
| October 29, 2024 | 13.44M |
| October 28, 2024 | 13.14M |
| October 25, 2024 | 14.76M |
| October 24, 2024 | 15.07M |
| October 23, 2024 | 17.09M |
| October 22, 2024 | 13.95M |
| October 21, 2024 | 13.24M |
| October 18, 2024 | 14.36M |
| October 17, 2024 | 13.87M |
| October 16, 2024 | 14.56M |
| October 15, 2024 | 14.97M |
| October 14, 2024 | 13.75M |
| October 11, 2024 | 14.46M |
| October 10, 2024 | 15.17M |
| October 09, 2024 | 14.15M |
| October 08, 2024 | 11.21M |
| October 07, 2024 | 12.13M |
| October 04, 2024 | 12.13M |
| October 03, 2024 | 11.01M |
| October 02, 2024 | 11.52M |
| October 01, 2024 | 11.11M |
| September 30, 2024 | 11.01M |
| September 27, 2024 | 12.23M |
| Date | Value |
|---|---|
| September 26, 2024 | 11.72M |
| September 25, 2024 | 11.62M |
| September 24, 2024 | 6.549M |
| September 23, 2024 | 6.955M |
| September 20, 2024 | 7.766M |
| September 19, 2024 | 8.780M |
| September 18, 2024 | 8.172M |
| September 17, 2024 | 8.273M |
| September 16, 2024 | 6.701M |
| September 13, 2024 | 3.814M |
| September 12, 2024 | 2.144M |
| September 11, 2024 | 4.116M |
| September 10, 2024 | 4.775M |
| September 09, 2024 | 5.434M |
| September 06, 2024 | 5.028M |
| September 05, 2024 | 5.434M |
| September 04, 2024 | 5.942M |
| September 03, 2024 | 6.498M |
| August 30, 2024 | 7.158M |
| August 29, 2024 | 7.360M |
| August 28, 2024 | 6.245M |
| August 27, 2024 | 5.738M |
| August 26, 2024 | 4.574M |
| August 23, 2024 | 5.434M |
| August 22, 2024 | 4.928M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-19.60M
Minimum
Dec 12 2022
227.05M
Maximum
Dec 20 2019
22.28M
Average
7.080M
Median
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals Inc | 701.92M |
| Edesa Biotech Inc | 8.676M |
| Lexaria Bioscience Corp | 25.11M |
| Xenon Pharmaceuticals Inc | 2.393B |
| ESSA Pharma Inc | 100.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.617M |
| Total Expenses (Quarterly) | 4.963M |
| EPS Diluted (Quarterly) | -0.24 |
| Earnings Yield | -45.59% |
| Normalized Earnings Yield | -159.59 |